Shares in Emyria Ltd (ASX: EMD) are falling today after the company shared news of a psychedelic therapy program targeting post traumatic stress disorder (PTSD). At its intraday low, the Emyria share price has fallen by 5%.
At the time of writing, it has slightly recovered. Currently, the Emyria share price is down 3.85% – trading for 25 cents.
Let’s take a closer look at the drug development and clinical services company’s news.
Emyria’s MDMA-assisted therapy trial
Emyria – formerly known as Emerald Clinics Limited – is set to sponsor a clinical trial targeting treatment resistant PTSD with MDMA-assisted therapy.
The trial has been developed in partnership with Mind Medicine Australia, a charity working to help end…